Skip to content

Study of Cytrix Use in Pelvic Floor Prolapse Treatment

Clinical Investigation of Fetal Bovine Dermis Material (Cytrix) for Use in the Treatment of Pelvic Floor Prolapse

Status
Completed
Phases
Phase 4
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT01244165
Enrollment
45
Registered
2010-11-19
Start date
2002-01-31
Completion date
2006-10-31
Last updated
2010-11-19

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Vaginal Vault Prolapse

Brief summary

To evaluate safety and effectiveness of using the fetal bovine dermis (Cytrix) in the treatment of pelvic organ prolapse.

Interventions

DEVICECytrix
OTHEROther treatments for pelvic organ prolapse

Treatments for pelvic organ prolapse using other products (standard of care for treatment of pelvic organ prolapse)

Sponsors

Boston Scientific Corporation
Lead SponsorINDUSTRY

Study design

Allocation
NON_RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
NONE

Eligibility

Sex/Gender
FEMALE
Age
30 Years to 85 Years
Healthy volunteers
Yes

Inclusion criteria

* Female \>30 years of age * Willing and able to comply w/ the study procedures and provide written informed consent to participate in the study. * Diagnosed with pelvic organ prolapse with or without pelvis floor dysfunction * Patient is willing to complete PFDI-SF20 and PISQ-12 questionnaires at 6 and 12 months post-operatively * Patient is willing to answer phone questionnaires at 2 weeks, 6 weeks, and 3 months * Patients with a history of pelvic surgery (cystocele/anterior repair, hysterectomy, vault suspension, etc) prior to this procedure are allowed to participate in the study except if the patient had a dermal graft implanted.

Exclusion criteria

* Patients who, in the clinical judgment of the investigator, are not suitable for this study * Patients who are, in the Investigators opinion, mentally or legally incapacitated preventing informed consent or unable to read or understand written material. * Patients who have participated in an investigational study within 30 days of study entry that may impact analysis of this device or have previously participated in the current trial * Patient whose pelvic organ prolapse is Stage I * Patient with Diabetes Mellitus type I or II * Patient with morbid obesity (weight parameters determined by physician) * Patient with undiagnosed pelvic mass outside of the uterus (not expected to be functional in nature) * Patient with unexplained abnormal menstrual bleeding * Patient with any acute or chronic infection (kidney, bladder, lung, etc) * Patient with coagulopathy * Patient participating in other investigational device or drug study * Patients must not be pregnant * Patients with life expectancy less than 2 years * Patients with known or suspected hypersensitivity to collagen or bovine products * Patients with preexisting local or systemic infection * Patients with a history of soft tissue pathology where the implant is to be placed * Patients with any pathology that would limit the blood supply and compromise healing * Patient diagnosed with autoimmune connective tissue disease

Design outcomes

Primary

MeasureTime frameDescription
Comparison of Pelvic Floor Distress Inventory (PFDI-SF20) questionnaire results between Cytrix Group and Control Group6 monthsComparison of Pelvic Floor Distress Inventory (PFDI-SF20) questionnaire results in Cytrix treated patients compared to patients in the retrospective historical control group where available.
Number of patients reporting intra-operative complicationsat procedure
number of treated patients reporting post-operative adverse events6 Months
Patient healing time6 Monthslength of hospital stay and pain medication
Incidence of complication in Cytrix treated patients compared to patients in the historical control group6 monthsIncidence of complication in Cytrix treated patients compared to patients in the historical control group
Patient satisfaction after Pelvic Organ Prolapse surgery using Cytrix3 monthsPhone-Patient Questionnaire
Comparison of phone patient questionnaire results between Cytrix Group and Control Group6 monthsComparison of phone patient questionnaire results in Cytrix treated patients compared to patients in the retrospective historical control group where available.

Secondary

MeasureTime frameDescription
Physician satisfaction in the treatment of patients with pelvic floor prolapse using Cytrix6 monthsPhysician satisfaction in the treatment of patients with pelvic floor prolapse using Cytrix versus any other product currently being the standard method of care; 1. handling characteristics 2. conformity to the surgical site 3. ease of suture 4. procedure length of time

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Mar 30, 2026